Cargando…

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)

The prognosis of adult soft tissue sarcoma (STS) patients with metastases is generally poor. As little is known about the impact of the involvement of different metastatic sites and the extent of pulmonary lesions on the outcome for patients receiving first‐line chemotherapy, we aimed to establish p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindner, Lars H., Litière, Saskia, Sleijfer, Stefan, Benson, Charlotte, Italiano, Antoine, Kasper, Bernd, Messiou, Christina, Gelderblom, Hans, Wardelmann, Eva, Le Cesne, Axel, Blay, Jean‐Yves, Marreaud, Sandrine, Hindi, Nadia, Desar, Ingrid M.E., Gronchi, Alessandro, van der Graaf, Winette T.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947111/
https://www.ncbi.nlm.nih.gov/pubmed/29383713
http://dx.doi.org/10.1002/ijc.31286
_version_ 1783322305528594432
author Lindner, Lars H.
Litière, Saskia
Sleijfer, Stefan
Benson, Charlotte
Italiano, Antoine
Kasper, Bernd
Messiou, Christina
Gelderblom, Hans
Wardelmann, Eva
Le Cesne, Axel
Blay, Jean‐Yves
Marreaud, Sandrine
Hindi, Nadia
Desar, Ingrid M.E.
Gronchi, Alessandro
van der Graaf, Winette T.A.
author_facet Lindner, Lars H.
Litière, Saskia
Sleijfer, Stefan
Benson, Charlotte
Italiano, Antoine
Kasper, Bernd
Messiou, Christina
Gelderblom, Hans
Wardelmann, Eva
Le Cesne, Axel
Blay, Jean‐Yves
Marreaud, Sandrine
Hindi, Nadia
Desar, Ingrid M.E.
Gronchi, Alessandro
van der Graaf, Winette T.A.
author_sort Lindner, Lars H.
collection PubMed
description The prognosis of adult soft tissue sarcoma (STS) patients with metastases is generally poor. As little is known about the impact of the involvement of different metastatic sites and the extent of pulmonary lesions on the outcome for patients receiving first‐line chemotherapy, we aimed to establish prognostic factors for STS patients with lung metastases only. A retrospective, exploratory analysis was performed on 2,913 metastatic STS patients who received first‐line chemotherapy. Detailed information from 580 patients who had lung metastases only, was used for prognostic factor analysis. Patients with lung metastases only were more often asymptomatic and had undergone complete primary tumor resection more frequently compared to patients with additional metastases outside the lung or without lung metastases. For extremity STS, the incidence of lung metastases only was much higher compared to non‐extremity STS. Lung involvement only was an independent favorable prognostic factor for overall survival (OS) with regard to metastatic site. Within this subgroup, in a multivariate model, other factors associated with improved OS included: good performance status (PS), no progression at primary site, low histological grade, younger age, long interval between initial diagnosis and trial registration, and smaller diameter of the largest lung lesion. This unique analysis on prognostic factors in STS patients with lung metastases confirms well‐known patient factors (such as age and PS), and tumor characteristics (including tumor grade, interval between primary diagnosis, and metastases), but also identifies diameter of the largest lung lesion as a new prognostic factor. Knowledge about these factors may support decision‐making within multidisciplinary tumor boards.
format Online
Article
Text
id pubmed-5947111
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59471112018-05-17 Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) Lindner, Lars H. Litière, Saskia Sleijfer, Stefan Benson, Charlotte Italiano, Antoine Kasper, Bernd Messiou, Christina Gelderblom, Hans Wardelmann, Eva Le Cesne, Axel Blay, Jean‐Yves Marreaud, Sandrine Hindi, Nadia Desar, Ingrid M.E. Gronchi, Alessandro van der Graaf, Winette T.A. Int J Cancer Cancer Therapy and Prevention The prognosis of adult soft tissue sarcoma (STS) patients with metastases is generally poor. As little is known about the impact of the involvement of different metastatic sites and the extent of pulmonary lesions on the outcome for patients receiving first‐line chemotherapy, we aimed to establish prognostic factors for STS patients with lung metastases only. A retrospective, exploratory analysis was performed on 2,913 metastatic STS patients who received first‐line chemotherapy. Detailed information from 580 patients who had lung metastases only, was used for prognostic factor analysis. Patients with lung metastases only were more often asymptomatic and had undergone complete primary tumor resection more frequently compared to patients with additional metastases outside the lung or without lung metastases. For extremity STS, the incidence of lung metastases only was much higher compared to non‐extremity STS. Lung involvement only was an independent favorable prognostic factor for overall survival (OS) with regard to metastatic site. Within this subgroup, in a multivariate model, other factors associated with improved OS included: good performance status (PS), no progression at primary site, low histological grade, younger age, long interval between initial diagnosis and trial registration, and smaller diameter of the largest lung lesion. This unique analysis on prognostic factors in STS patients with lung metastases confirms well‐known patient factors (such as age and PS), and tumor characteristics (including tumor grade, interval between primary diagnosis, and metastases), but also identifies diameter of the largest lung lesion as a new prognostic factor. Knowledge about these factors may support decision‐making within multidisciplinary tumor boards. John Wiley and Sons Inc. 2018-02-14 2018-06-15 /pmc/articles/PMC5947111/ /pubmed/29383713 http://dx.doi.org/10.1002/ijc.31286 Text en © 2018 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Therapy and Prevention
Lindner, Lars H.
Litière, Saskia
Sleijfer, Stefan
Benson, Charlotte
Italiano, Antoine
Kasper, Bernd
Messiou, Christina
Gelderblom, Hans
Wardelmann, Eva
Le Cesne, Axel
Blay, Jean‐Yves
Marreaud, Sandrine
Hindi, Nadia
Desar, Ingrid M.E.
Gronchi, Alessandro
van der Graaf, Winette T.A.
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
title Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
title_full Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
title_fullStr Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
title_full_unstemmed Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
title_short Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
title_sort prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: an exploratory, retrospective analysis of the european organization for research and treatment of cancer‐soft tissue and bone sarcoma group (eortc‐stbsg)
topic Cancer Therapy and Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947111/
https://www.ncbi.nlm.nih.gov/pubmed/29383713
http://dx.doi.org/10.1002/ijc.31286
work_keys_str_mv AT lindnerlarsh prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT litieresaskia prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT sleijferstefan prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT bensoncharlotte prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT italianoantoine prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT kasperbernd prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT messiouchristina prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT gelderblomhans prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT wardelmanneva prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT lecesneaxel prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT blayjeanyves prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT marreaudsandrine prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT hindinadia prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT desaringridme prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT gronchialessandro prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg
AT vandergraafwinetteta prognosticfactorsforsofttissuesarcomapatientswithlungmetastasesonlywhoarereceivingfirstlinechemotherapyanexploratoryretrospectiveanalysisoftheeuropeanorganizationforresearchandtreatmentofcancersofttissueandbonesarcomagroupeortcstbsg